Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Results | NCT02260531 | the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial, than in the ER+ and/or PR+ group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT02260531', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1 - Cabozantinib, Trastuzumab for HER2+', ' HER2-positive', ' Cabozantinib- orally administered daily per treatment cycle', ' Trastuzumab- IV administered once per cycle', ' MRI- Baseline, Cycle 2 Day 1, and every 2 cycles', ' Magn... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7d7a9a69-533a-4480-b2e7-aa59eb8a738b | |
Single | Results | NCT00036270 | In total Less than 10% of patients in the primary trial either had a disease relapse or died. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00036270', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Exemestane (Aromasin®) 25 mg QD for 5 years.', 'INTERVENTION 2: ', ' Tamoxifen Followed by Exemestane', ' Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 2... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c6fc8336-7c74-443e-9548-3bbafe21fc37 | |
Single | Eligibility | NCT01351376 | Patients currently prescribed Diuretics are excluded from the primary trial. | Entailment | [
5,
18
] | [] | {'Clinical Trial ID': 'NCT01351376', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' CDT + inactive LLL', ' Low Level Laser Therapy: Placebo LLL combined with CDT', 'INTERVENTION 2: ', ' LLL Combined With CDT', ' CDT + active LLL', ' Low Level Laser: Active LLL combined with CDT'], 'Eligibility': ['Inclusion C... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9035000f-d87b-439f-882a-e6e30694e391 | |
Comparison | Intervention | NCT03210220 | NCT00290745 | Unlike the primary trial, the secondary trial does not test Gonadotrophin-releasing Hormone Analogues or medical devices. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT03210220', 'Intervention': ['INTERVENTION 1: ', ' Pecs Group', ' Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral bran... | {'Clinical Trial ID': 'NCT00290745', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen or Letrozole', ' tamoxifen or letrozole work in treating women with ductal carcinoma in situ', ' letrozole', ' tamoxifen citrate', ' conventional surgery', ' neoadjuvant therapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' ... | 522ca0ec-aeb0-4083-a274-ab58c2cddb8a |
Single | Adverse Events | NCT01127763 | There were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial. | Entailment | [
3,
6
] | [] | {'Clinical Trial ID': 'NCT01127763', 'Intervention': ['INTERVENTION 1: ', ' RAD001+Carboplatin', ' Carboplatin (starting dose was initially AUC 6, later decreased to AUC 5, then AUC 4) every 3 weeks as IV infusion and RAD001 as 5 mg pill each day until disease progression or unacceptable toxicity.', 'RAD001', 'Carbop... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 46d65581-7a0a-423b-907e-662c1f5843cc | |
Comparison | Intervention | NCT02413008 | NCT02725801 | The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial are only apllied once. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02413008', 'Intervention': ['INTERVENTION 1: ', ' 0.005% Estriol Vaginal Gel', ' Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly admini... | {'Clinical Trial ID': 'NCT02725801', 'Intervention': ['INTERVENTION 1: ', ' One-port', ' intervention is placement of one-port tissue expander at time of reconstruction', ' Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruc... | f4ea6e98-75e1-43a0-8202-548bb7ceb66c |
Single | Results | NCT00534417 | The median TTP for patients in cohort one of the primary trial is NA. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00534417', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine and Fulvestrant', ' Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid i... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c3a618d6-2c2e-4ed6-bfe7-88d28ec18240 | |
Single | Adverse Events | NCT00129935 | There were more cases of embolisms in cohort 2 of the primary trial than cohort 1. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT00129935', 'Intervention': ['INTERVENTION 1: ', ' Arm A: EC-T', ' Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycle... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 932728c5-2e7f-401f-be64-e90597ff2ce2 | |
Single | Results | NCT00291577 | It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00291577', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib in Combination With Docetaxel', ' Sunitinib (SU011248) orally (PO) for 2 weeks every 3 weeks (2 weeks on, then 1 week off = Schedule 2/1) starting on Day 2 (Cycle 2, Day 3 only for those subjects included in the Pharmacokinetic [PK]... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 54ad9406-852c-40fc-bd0e-8e7e81eacc71 | |
Comparison | Eligibility | NCT00201760 | NCT00127933 | Patients must have a triple negative infiltrating breast carcinoma to participate in the secondary trial or the primary trial. | Contradiction | [
0,
1,
2
] | [
0,
3
] | {'Clinical Trial ID': 'NCT00201760', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 Gemcitabine/Cisplatin/Trastuzumab', ' Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not adm... | {'Clinical Trial ID': 'NCT00127933', 'Intervention': ['INTERVENTION 1: ', ' HER2-Neu Negative', ' Dose and route per treatment cycle (Q3W):', ' Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1', ' HER2-neu negative: capecitabine + docetaxel', ' Duration: Four 3-week t... | 7021a4a9-b474-4568-a3b8-015a50c9d9cc |
Single | Intervention | NCT00290745 | There is no radiotherapy or educational part of the intervention used in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT00290745', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen or Letrozole', ' tamoxifen or letrozole work in treating women with ductal carcinoma in situ', ' letrozole', ' tamoxifen citrate', ' conventional surgery', ' neoadjuvant therapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 24eced44-40b2-4365-abd3-42eb13220cf0 | |
Comparison | Intervention | NCT01448447 | NCT03252145 | the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT01448447', 'Intervention': ['INTERVENTION 1: ', ' Sole Method', ' patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS', ' Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions ... | {'Clinical Trial ID': 'NCT03252145', 'Intervention': ['INTERVENTION 1: ', ' Manual Lymph Drainage', ' Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb', ' Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb vol... | 3e2dda3a-815f-4681-a470-009d9f9b30d6 |
Comparison | Intervention | NCT01653964 | NCT02660788 | The interventions in the primary trial and the secondary trial are similar, as they are testing the same medication, however they are not using the same doses. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT01653964', 'Intervention': ['INTERVENTION 1: ', ' Molecular Breast Imaging', ' Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi.'], 'Eligibility': ['Inclusion Criteria:', ' Subgroup 1, Patients with breast lesions:', ' -At ... | {'Clinical Trial ID': 'NCT02660788', 'Intervention': ['INTERVENTION 1: ', ' Control Arm', ' Mail', ' Standard Reminder Postcard', 'INTERVENTION 2: ', ' Family Physician Reminder Letter Arm', ' Mail', ' Standard Reminder Postcard', ' Family Physician Reminder Letter'], 'Eligibility': ['Inclusion Criteria:', ' Ac... | 1a293e7c-691f-4f93-bab8-6bf5d9b3f904 |
Single | Results | NCT00444535 | Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00444535', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib + Bevacizumab', ' Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg intravenously [IV] every two weeks)'], 'Eligibility': ['Inclusion criteria:', ' Females that are at least 18 years of age.', ' Women of childb... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a87e6e20-c7d0-4941-9933-204fab99b299 | |
Single | Adverse Events | NCT01940497 | There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24
] | [] | {'Clinical Trial ID': 'NCT01940497', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab (Vial): Adjuvant', ' Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6c3427a8-27a1-459c-9fbc-175649210868 | |
Single | Eligibility | NCT00101400 | A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/µl and total bilirubin < 1.2 x ULN are eligilbe for the primary trial. | Contradiction | [
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00101400', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib (Nexavar, BAY43-9006)', ' Sorafenib 400 mg administered twice daily (b.i.d.)'], 'Eligibility': ['Inclusion Criteria:', ' Age > 18 years', ' Women with prior histologically documented diagnosis of breast cancer', ' Subjects with m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 883bec6a-bce2-4e60-9304-49a056e66df7 | |
Comparison | Adverse Events | NCT02402764 | NCT00490646 | There were no cases of extravasation in either the primary trial or the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT02402764', 'Intervention': ['INTERVENTION 1: ', ' Selinexor Treatment', ' Ten patients were treated with oral selinexor 60 mg twice per week (on days 1 and 3) on a schedule of 3 weeks on and 1 week off, each four-week cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirm... | {'Clinical Trial ID': 'NCT00490646', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab 2 mg/kg + Ixabepilone 40 mg/m^2 IV', ' trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptabl... | 8720143a-2611-4502-a5ee-da4e641df918 |
Single | Intervention | NCT02186015 | Women in cohort A and B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT02186015', 'Intervention': ['INTERVENTION 1: ', ' Cholecalciferol', ' Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks.', 'INTERVENTION 2: ', ' No Cholecalciferol', ' Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no in... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0fdda7a2-4119-40a7-84f3-6c5c6077df49 | |
Single | Adverse Events | NCT01273896 | There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial. | Contradiction | [
0,
2,
8
] | [] | {'Clinical Trial ID': 'NCT01273896', 'Intervention': ['INTERVENTION 1: ', ' STA-9090', ' This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.', ' STA-9090: All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecut... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e7eae332-6b6a-41e0-aa31-86a781fd373f | |
Single | Intervention | NCT01439945 | In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
7,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01439945', 'Intervention': ['INTERVENTION 1: ', ' Low Dose Magnesium Oxide (800 mg/Day)', ' Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', '... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9a52d5d4-ff71-42ee-8672-ec4ac3cfd591 | |
Comparison | Intervention | NCT01735175 | NCT01216319 | the secondary trial and the primary trial are both testing Biodesign interventions. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01735175', 'Intervention': ['INTERVENTION 1: ', ' LA-EP2006', ' During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.', ' LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemothe... | {'Clinical Trial ID': 'NCT01216319', 'Intervention': ['INTERVENTION 1: ', ' Nipple Reconstruction Cylinder', ' Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder'], 'Eligibility': ['Inclusion Criteria:', ' Patient presents with a history of breast cancer, having previously completed either uni- or bi-l... | c09b9f7c-2d22-4c44-a79d-32929530dd9e |
Single | Results | NCT00003199 | The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20
] | [] | {'Clinical Trial ID': 'NCT00003199', 'Intervention': ['INTERVENTION 1: ', ' TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer', ' See Detailed Description.', ' tamoxifen citrate: Given orally', ' busulfan: Given orally', ' thiotepa: Given IV', ' melphalan: Given IV', ' aldesleukin: Given SC', ' sargramosti... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6f143256-52e4-40b7-950c-5c892f8632b9 | |
Single | Eligibility | NCT00217399 | To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions. | Entailment | [
3,
4,
5,
8
] | [] | {'Clinical Trial ID': 'NCT00217399', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib and Anastrozole', ' All patients receive sorafenib and anastrozole.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed breast cancer', ' Metastatic disease', ' Measurable disease, defined as >=1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d2718f05-1d35-4c84-a054-06a3fe4a0a9c | |
Single | Adverse Events | NCT01427933 | Neutropenia was the most common adverse event for patients in cohort 1 of the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT01427933', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab and Eribulin', ' Ramucirumab (IMC-1121B) 10 mg/kg administered by intravenous (IV) infusion on Day 1 of each 3-week cycle', ' Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle', 'INTERVENTION 2: ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7f49cafd-3a27-4fc8-872d-914b9176442e | |
Single | Adverse Events | NCT01998906 | The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial. | Entailment | [
0,
3,
4
] | [] | {'Clinical Trial ID': 'NCT01998906', 'Intervention': ['INTERVENTION 1: ', ' HER2+ TC', ' Participants with HER2+ breast cancer received treatment as follows:', ' Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25 | |
Comparison | Eligibility | NCT00428922 | NCT00499083 | Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago, are not eligible for either the primary trial or the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
26
] | {'Clinical Trial ID': 'NCT00428922', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Bevacizumab, and Docetaxel', ' Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed breast cancer with evidence of metastatic disease', ' HER... | {'Clinical Trial ID': 'NCT00499083', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Patients with HER-2/neu negative tumors received therapeutic autologous dendritic cells: injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.', ' Adjuvant hormo... | 3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8 |
Comparison | Eligibility | NCT00365599 | NCT01771666 | Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial | Entailment | [
0,
10,
12,
15,
25
] | [
0,
6
] | {'Clinical Trial ID': 'NCT00365599', 'Intervention': ['INTERVENTION 1: ', ' Vorinostat and Tamoxifen', ' Vorinostat and Tamoxifen as outlined in Intervention Descriptions'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have cytologically/histologically documented locally advanced or metastatic breast cance... | {'Clinical Trial ID': 'NCT01771666', 'Intervention': ['INTERVENTION 1: ', ' ISB and IC-Green Dye', ' The dose of Isosulfan blue (ISB) dye is 3 to 5 mL and Indocyanine green solution will be started at 1 mg/mL. If fluorescence is not detected with this dose, then it will be increased by 50%. A gamma probe [Neoprobe 20... | 4ab00376-83a4-467e-8a1e-6b8b1643a8f0 |
Comparison | Adverse Events | NCT01565499 | NCT01234402 | None of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different heart related issues. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT01565499', 'Intervention': ['INTERVENTION 1: ', ' Nab-Paclitaxel', ' The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.', 'Nab-paclitaxel'], 'Eligibility': ['Inclusion Criteria:', ' Female patients with histologically conf... | {'Clinical Trial ID': 'NCT01234402', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab + Capecitabine', ' Participants received 10 milligram per kilogram (mg/kg) Ramucirumab intravenously on day 1 of 21 days cycle along with 1000 milligram per square meter (mg/m^2) of Capecitabine twice daily orally on days 1 to 14 ... | e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1 |
Comparison | Intervention | NCT02699983 | NCT00994279 | Neither the primary trial or the secondary trial require participants to practice yoga. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT02699983', 'Intervention': ['INTERVENTION 1: ', ' Group I (SparkPeople Program)', ' Participants receive training on how to use the SparkPeople website, self-monitor their diet using the SparkPeople tool, and to self-monitor their activity daily using the Fitbit monitoring device.', ' Parti... | {'Clinical Trial ID': 'NCT00994279', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Yoga Intervention', ' Yoga Intervention', ' Yoga: Yoga sessions', 'INTERVENTION 2: ', ' Arm 2: Educational Wellness Group', ' Educational Wellness Group', ' Education: Educational Wellness Group'], 'Eligibility': ['Inclusion Criter... | 407369fa-92ba-4994-8a0f-d372995f3241 |
Comparison | Results | NCT01004172 | NCT00802945 | the primary trial and the secondary trial both evaluate response rates, however the primary trial studies CNS response, whereas the secondary trial studies tumor response, additionally, they test different treatments. | Entailment | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT01004172', 'Intervention': ['INTERVENTION 1: ', ' Carboplatin, Bevacizumab, Trastuzumab (if HER2+)', ' Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days.', ' carboplatin: AUC=5 dose given intravenously on day 8 of cycle one an... | {'Clinical Trial ID': 'NCT00802945', 'Intervention': ['INTERVENTION 1: ', ' NKTR-102 14 Day', ' NKTR-102: NKTR-102 given on a q14 day schedule', 'INTERVENTION 2: ', ' NKTR-102 21 Days', ' NKTR-102: NKTR-102 given on a q21 day schedule'], 'Eligibility': ['Inclusion Criteria:', ' Inoperable metastatic or locally adv... | 05e50a3d-d5b2-4fe6-9709-c884c89c5f71 |
Single | Adverse Events | NCT00546104 | 1 patient in the primary trial suffered from a blood clot blocking their blood vessels. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00546104', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib', '50mg-100mg po BID'], 'Eligibility': ['Inclusion Criteria:', ' Measurable Stage IV or inoperable Stage III advanced breast cancer.', ' There is no limit on the number of prior therapies.', ' At least 3 weeks since prior chemothe... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 59fd53e4-b38c-4018-bafc-6fd7f7becebe | |
Single | Adverse Events | NCT01926886 | There were no cases of Cellulitis, Nausea or Anaemia in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01926886', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants received trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c17eaeab-4e99-4cc4-8681-ae6ccddba572 | |
Single | Eligibility | NCT00952692 | Candidates for the primary trial must have adequate renal and hepatic function, and must not be currently receiving amiodarone or have received amiodarone in the 6 months | Entailment | [
0,
27,
28,
38,
43
] | [] | {'Clinical Trial ID': 'NCT00952692', 'Intervention': ['INTERVENTION 1: ', ' dHER2 + AS15 ASCI + Lapatinib', ' Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine. The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 621d06ac-12dd-42c2-a012-15c1d94a4f0b | |
Single | Adverse Events | NCT00193063 | In the primary trial patient cohort, 3 different types of infections are observed, these are pneumonia, urinary tract and Athlete's foot. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00193063', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine/Trastuzumab', ' All patients entering this trial received treatment with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8,and 15 of a 28-day cycle. Trastuzumab was ad... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 021e79d2-ce70-43cf-aac9-fa8d4c8d3770 | |
Single | Intervention | NCT00486525 | The difference between the two cohorts of the primary trial is that cohort 1 participated in a Hatha yoga, whereas cohort 2 abstained from yoga. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00486525', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Yoga Therapy', ' Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients were also encouraged to practice yoga at home. Patients recorded their total home/class practice time in weekly logs.', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 06aa0fbc-fe49-4715-88cc-507646f6323f | |
Comparison | Eligibility | NCT00754325 | NCT00399529 | the secondary trial and the primary trial both accept patients with progesterone receptors(PgR+) adenocarcinoma of the breast. | Contradiction | [
1,
2
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00754325', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant and Dasatinib', ' Arm 1: Participants in this group received a drug regimen that consisted of both fulvestrant and dasatinib.', ' Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day... | {'Clinical Trial ID': 'NCT00399529', 'Intervention': ['INTERVENTION 1: ', ' Allo GM-CSF-secreting Vaccine, Trastuzumab, Cyclophosphamide', ' Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part ... | 21947261-bbef-4d3a-adda-02bb4a91a3ca |
Comparison | Adverse Events | NCT00617942 | NCT00388726 | the secondary trial had a lower total number of patients experiencing adverse events compared to the primary trial. | Contradiction | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00617942', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1', '[Not Specified]', 'INTERVENTION 2: ', ' Cohort 2', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Histologically documented adenocarcinoma of the breast', ' ANC > 1000 cells', ' Female; age > 18; Zubrod PS 0-1', '... | {'Clinical Trial ID': 'NCT00388726', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/kg^2', ' Eribulin Mesylate 1.4 mg/kg^2 on Days 1 and 8', 'INTERVENTION 2: ', " Treatment of Physician's Choice", " Treatment of Physician's Choice"], 'Eligibility': ['Inclusion Criteria:', ' Female patients with hi... | 71daae7c-3ee5-4451-91e2-273d8ff55aae |
Single | Adverse Events | NCT00203502 | Every single patient in the primary trial experienced at least 1 adverse event. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00203502', 'Intervention': ['INTERVENTION 1: ', ' Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', ' Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2', ' + Avastin 15 mg/kg', ' Q 3 weeks X 4 cycles', ' Bevacizumab/Avastin: IV 15mg/kg 21 days', ' Cyclophosphamide: 500mg per meter... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37 | |
Single | Adverse Events | NCT01644890 | Throughout the primary trial, one patient developed issues with their vision. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT01644890', 'Intervention': ['INTERVENTION 1: ', ' NK105', ' received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle', 'INTERVENTION 2: ', ' Paclitaxel', ' received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle'], 'Eligibility': ['Inclusion Criteria:', ' Written inf... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7d22937b-9823-45fa-a914-261f993e4d64 | |
Single | Adverse Events | NCT01940497 | There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24
] | [] | {'Clinical Trial ID': 'NCT01940497', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab (Vial): Adjuvant', ' Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 507a4189-4905-4752-8348-d715a5ce3962 | |
Single | Results | NCT00096356 | the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00096356', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 - CoQ10 & Vitamin E', ' CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day.', 'INTERVENTION 2: ', ' Arm 2 - Placebo & Vitamin E', ' Placebo-Vitamin E 100 mg/day in 3 doses'], 'Eligibility': ['Inclusion... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 24001e83-6a8c-4f67-9c24-55dc285c4cc2 | |
Single | Intervention | NCT00513695 | filgrastim is the only drug in the primary trial given by subcutaneous injection. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00513695', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Neoadjuvant Chemotherapy Before Surgery)', ' Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unac... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d179396d-94fe-465f-a4f1-e7c3291a0a9a | |
Comparison | Adverse Events | NCT00796978 | NCT01276041 | More patients in the secondary trial suffered from oedema in their limbs, compared to patients in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | {'Clinical Trial ID': 'NCT00796978', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' trastuzumab: Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.', ' laboratory biomarker analysis: Blood... | {'Clinical Trial ID': 'NCT01276041', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab in Combination With Trastuzumab and Paclitaxel', ' This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.'], 'Eligibility': ['Inclus... | 4b893eeb-80a4-4a83-8df5-b5c668ce55b1 |
Single | Adverse Events | NCT00448279 | In total there were more adverse events in cohort 1 of the primary trial, than in cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00448279', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy Alone', " Participants received chemotherapy until disease progression, unacceptable toxicity, or death; the schedule and dose at the investigator's discretion and per local prescribing guidelines and standard center practice. Al... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 44cd16f5-6638-4d82-9121-1941eb8ce4b5 | |
Comparison | Intervention | NCT01697345 | NCT00513292 | Fluorouracil, epirubicin, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01697345', 'Intervention': ['INTERVENTION 1: ', ' FSFI Total Score (Pretest)', ' Administered to participants prior to starting vaginal testosterone therapy.', 'INTERVENTION 2: ', ' FSFI Total Score (Postteset)', ' Testosterone USP micronized powder supplied by Medisca Pharmacy was compoun... | {'Clinical Trial ID': 'NCT00513292', 'Intervention': ['INTERVENTION 1: ', ' FEC-75 Then Paclitaxel/Trastuzumab', ' Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 cour... | 50ac2c53-3b63-4507-8712-41f8c257b4da |
Comparison | Eligibility | NCT02322814 | NCT00356148 | A patient with Histologically confirmed triple-negative breast cancer, with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction, could be eligible for both the secondary trial and the primary trial. | Entailment | [
0,
2,
22,
15,
33
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT02322814', 'Intervention': ['INTERVENTION 1: ', ' Cohort I: Cobimetinib, Paclitaxel', ' Participants received a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of ... | {'Clinical Trial ID': 'NCT00356148', 'Intervention': ['INTERVENTION 1: ', ' Prophylaxis Group', ' patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis', 'INTERVENTION 2: ', ' No Prophylaxis Group', ' Patients who are BMI over 25 and not receive antibiotic prophylaxis'], 'Eligibility': ['Inclu... | 14607d45-9aef-458d-89cc-d47c62c23322 |
Single | Adverse Events | NCT01300351 | At least 1 participant in the primary trial showed signs of poor liver function. | Entailment | [
0,
7
] | [] | {'Clinical Trial ID': 'NCT01300351', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 500 mg', ' Fulvestrant 500 mg intramuscular (im) every 28 (± 3) days plus an additional 500 mg on Day 15 (± 3) of first month only', 'INTERVENTION 2: ', ' Fulvestrant 250 mg', ' Fulvestrant 250 mg im every 28 (± 3) days'], 'Elig... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d2961e96-bd3b-4994-aa7e-2b310eb6204e | |
Single | Intervention | NCT03106077 | Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT03106077', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Advanced Triple-Negative Breast Cancer (TNBC)', ' 6 mg/kg IMGN853 IV Q3W'], 'Eligibility': ['Inclusion Criteria:', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Confirmed invasive triple-negative bre... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8a5d7285-f4be-4e50-9057-19f74bcc410b | |
Single | Adverse Events | NCT00394251 | There were 4 different adverse events, for which 0 cases were recorded in cohort 1. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00394251', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 Subset', ' 260 mg/m2 ABI-007 (Abraxane) plus Bevacizumab for 4 cycles (weeks 9-16); Bevacizumab (weeks 17-46). Weeks 1-8 are excluded from this subset.', 'INTERVENTION 2: ', ' AC --> ABI-007', ' Adriamycin and Cytoxan plus Bevacizum... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 512990dd-45d2-4b31-b571-66735ff02308 | |
Comparison | Adverse Events | NCT00471276 | NCT00951665 | Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial. than cohort 1 of the primary trial . | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT00471276', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib', ' Sunitinib 37.5 milligrams (mg) daily by oral capsule in continuous daily dose (CDD) schedule. Dose adjustments, if needed, included a reduction to 25mg daily or escalation to 50mg daily anytime after Week 12.'], 'Eligibility': [... | {'Clinical Trial ID': 'NCT00951665', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib Regimen 1', ' Participants received T-DM1 Q3W + paclitaxel QW intravenously.', 'INTERVENTION 2: ', ' Phase Ib Regimen 2', ' Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.'], 'Eligibility': ['Inclusi... | 383db144-4bcd-4ebc-989c-b6ae7d282026 |
Single | Adverse Events | NCT00951665 | Most patients in cohort 1 of the primary trial died of unknown causes. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00951665', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib Regimen 1', ' Participants received T-DM1 Q3W + paclitaxel QW intravenously.', 'INTERVENTION 2: ', ' Phase Ib Regimen 2', ' Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.'], 'Eligibility': ['Inclusi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bfa07fb7-f8cb-4215-9bca-ddee8b3bea73 | |
Single | Eligibility | NCT00328783 | Patients with an FEV1 of 80% to 120% are ineligible for the primary trial. | Contradiction | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT00328783', 'Intervention': ['INTERVENTION 1: ', ' Active Breathing Coordinator', ' Patients breathe through the ABC device', ' Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissu... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 228e80ab-84d6-4b60-9960-dcdcbd78c03c | |
Single | Eligibility | NCT00896649 | prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial, neither is Adequate organ function or a particular racial or ethnic background. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00896649', 'Intervention': ['INTERVENTION 1: ', ' Single Arm Positron Emission Mammography and Questionnaire', ' questionnaire administration positron emission mammography', ' digital mammography: standard screening mammogram', ' questionnaire administration: Questionnaire regarding patien... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b7caad28-5fb2-4eb6-845e-8315cff97318 | |
Single | Eligibility | NCT00005957 | T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00005957', 'Intervention': ['INTERVENTION 1: ', ' Standard Breast Irradiation', ' radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.', 'INTERVENTION 2: ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 73c37b9c-e7ba-4c90-b26e-23b7a65509c4 | |
Single | Eligibility | NCT02287675 | Informed consent is obligatory for entry in the primary trial. | Entailment | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT02287675', 'Intervention': ['INTERVENTION 1: ', ' Lymphoseek', ' Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d5b81f6c-821a-4db5-8810-9cc47a952913 | |
Single | Results | NCT01202591 | 100% of patients in the primary trial suffered adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01202591', 'Intervention': ['INTERVENTION 1: ', ' AZD4547 80mg bd Cont + Ex 25mg', ' 80 mg AZD4547 BD continuous + 25 mg exemestane', 'INTERVENTION 2: ', ' AZD4547 40mg Cont + Ex 25mg', ' 40 mg AZD4547 BD continuous + 25 mg exemestane'], 'Eligibility': ['Inclusion Criteria:', ' Post-menop... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | cdba382e-894b-4f79-a8e2-ff818746adc5 | |
Comparison | Eligibility | NCT00971737 | NCT00392392 | Patients with tumors overexpressing HER-2 are eligible for the secondary trial, but not for the primary trial. | Contradiction | [
0,
1,
2,
3
] | [
0,
3
] | {'Clinical Trial ID': 'NCT00971737', 'Intervention': ['INTERVENTION 1: ', ' Cyclophosphamide and Vaccine Only', ' Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of ... | {'Clinical Trial ID': 'NCT00392392', 'Intervention': ['INTERVENTION 1: ', ' Nab-Paclitaxel/Bevacizumab/Trastuzumab', ' Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and b... | 0093175a-38cb-4f63-b391-709ac48158b8 |
Single | Adverse Events | NCT00846027 | None of the adverse events recorded for the primary trial occurred more than once. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00846027', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab + Paclitaxel + Gemcitabine', ' Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptabl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 19106207-4fa2-4cc4-8e22-6e5330bf05ce | |
Comparison | Intervention | NCT02597452 | NCT01929395 | the primary trial and the secondary trial both use 21 day cycles for their interventions up to a maximum of 10 and 4 cycles respectively. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT02597452', 'Intervention': ['INTERVENTION 1: ', ' Intelligent Breast Exam, iBE', ' Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for partic... | {'Clinical Trial ID': 'NCT01929395', 'Intervention': ['INTERVENTION 1: ', ' Phase 1: Addition of Supine MRI to Conventional Imaging', ' Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)'], 'Eligibility': ['Inclusion Criteria Phase 1', ' Age greater than/equal to 18 years', ' His... | a015685e-f744-4bb2-a6d3-893f081d6dcc |
Single | Intervention | NCT01487954 | All patients in the primary trial had to drink 4 cups of water, either Alkaline Water or Distilled, depending on which cohort they are in. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01487954', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Alkaline Water', ' Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.', ' alkaline w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b9578bae-6640-4ef1-ba2c-899b45c602ee | |
Single | Adverse Events | NCT01416389 | Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2. | Entailment | [
0,
10,
11,
14,
24,
25
] | [] | {'Clinical Trial ID': 'NCT01416389', 'Intervention': ['INTERVENTION 1: ', ' LY2523355 + Pegfilgrastim or Filgrastim', " LY2523355 administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Dosage determined by calculating participant's body surface area (5 milligrams per meter... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 405369ef-d216-4d81-a04f-46f36f466a19 | |
Comparison | Adverse Events | NCT00559754 | NCT02924883 | A higher percent of patients in cohort 1 of the secondary trial experienced stomatitis, than in cohort 1 of the primary trial. | Contradiction | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00559754', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel', ' Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevaci... | {'Clinical Trial ID': 'NCT02924883', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine + Placebo', ' Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or stu... | e424c65e-7c6f-43a4-95e4-6beb705d9903 |
Single | Results | NCT01466270 | The the primary trial placebo group had a better mean retention than the donepezil hydrochloride PO QD group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT01466270', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive donepezil hydrochloride PO QD.', ' donepezil hydrochloride: Given PO', 'INTERVENTION 2: ', ' Arm II', ' Patients receive placebo PO QD.', 'Placebo: Given PO'], 'Eligibility': ['INCLUSION CRITERIA:', ' Adults >18... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f2bd0a9c-74c4-443e-b666-0a0b3aa125e1 | |
Single | Eligibility | NCT00072293 | Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for the primary trial. | Entailment | [
3,
12
] | [] | {'Clinical Trial ID': 'NCT00072293', 'Intervention': ['INTERVENTION 1: ', ' Axillary Dissection', ' Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.', ' Axillary lymph node dissection: Axillary lymph node dissection', 'INTERVENTION... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a | |
Comparison | Intervention | NCT01156987 | NCT02234479 | Participants in the primary trial are assigned an intervention depending on their HIV diagnosis, whereas in the secondary trial the interventions are randomly assigned. | Contradiction | [
0,
1,
2,
3,
13,
14,
15,
16
] | [
0,
1,
2,
5,
6,
7
] | {'Clinical Trial ID': 'NCT01156987', 'Intervention': ['INTERVENTION 1: ', ' Healthy Volunteers', ' Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.', ' Magnetic resonance imaging: Patients and healthy volunteers will be... | {'Clinical Trial ID': 'NCT02234479', 'Intervention': ['INTERVENTION 1: ', ' Hydrophor (Group A)', ' Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing ... | 6843daf8-8136-4973-9bf2-62a622d5a890 |
Comparison | Adverse Events | NCT01828021 | NCT01326481 | Patients in the primary trial and the secondary trial did not have any of the same adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT01828021', 'Intervention': ['INTERVENTION 1: ', ' Margetuximab', ' Monotherapy of Anti-HER2 monoclonal antibody', ' Margetuximab: Anti-HER2 monoclonal antibody'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed invasive carcinoma of the breast', ' Treatm... | {'Clinical Trial ID': 'NCT01326481', 'Intervention': ['INTERVENTION 1: ', ' Carotuximab (TRC105) Plus Capecitabine', ' All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)'], 'Eligibility': ['Inclusion Criteria:', ' Histologically proven advanced solid ... | 2687b547-c225-4838-bbcd-99212a74d815 |
Single | Adverse Events | NCT00759785 | Only one adverse event is observed in patients from cohort 1 of the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00759785', 'Intervention': ['INTERVENTION 1: ', ' ER-positive Luminal B (ER+)', ' ER-positive Luminal B participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes.', 'INTERVENTION 2: ', ' Triple Negative (TN)', ' Triple Negative participants received a single d... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fadf7710-6e4d-49d6-82fc-4f3137b5e26b | |
Single | Adverse Events | NCT00074152 | All of the adverse event cases in the primary trial occurred in patients from cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT00074152', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Observation (+/- Radiation). Patients receive radiotherapy* within 6 months after surgery.', ' radiation therapy: Given within 6 months after surgery', 'INTERVENTION 2: ', ' Arm II', ' Chemotherapy (+/- Radiation). Within 10 week... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8c4e6f36-37b4-4bde-b518-08a6dc55f7a5 | |
Single | Intervention | NCT01439945 | In the primary trial Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
7,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01439945', 'Intervention': ['INTERVENTION 1: ', ' Low Dose Magnesium Oxide (800 mg/Day)', ' Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', '... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6c0896ac-db42-45b4-a6e2-620a27fd321a | |
Single | Adverse Events | NCT00432172 | All of the adverse events recorded in the primary trial occurred in patients from cohort 1. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18
] | [] | {'Clinical Trial ID': 'NCT00432172', 'Intervention': ['INTERVENTION 1: ', ' Group 2 (Basal) Standard Treatment', ' Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.', 'INTERVENT... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3a80ba8a-265f-4931-a9a8-b7e00e372599 | |
Comparison | Intervention | NCT01929395 | NCT01857882 | the primary trial only has one test cohort whereas the secondary trial has both a test and control group. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT01929395', 'Intervention': ['INTERVENTION 1: ', ' Phase 1: Addition of Supine MRI to Conventional Imaging', ' Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)'], 'Eligibility': ['Inclusion Criteria Phase 1', ' Age greater than/equal to 18 years', ' His... | {'Clinical Trial ID': 'NCT01857882', 'Intervention': ['INTERVENTION 1: ', ' Decision Support Workshop', ' The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.', ' Decision Support Workshop: Incorporates... | df4b98f2-7ca9-4855-8d94-d62407ff8535 |
Comparison | Adverse Events | NCT01015131 | NCT00312208 | the primary trial records instances of Rectal Hemorrhage within its patient cohort, whereas the secondary trial records Vaginal hemorrhages. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT01015131', 'Intervention': ['INTERVENTION 1: ', ' All Participants', ' Participants who underwent 18-FLT positron emission tomography (PET) and standard of care (SOC) neo-adjuvant chemotherapy'], 'Eligibility': ['Inclusion Criteria:', ' Has newly-diagnosed stage IIB/IIIA/IIIB locally advanc... | {'Clinical Trial ID': 'NCT00312208', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)', ' AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks f... | 5d2542fa-5482-4aff-af29-80875a0a9dcc |
Comparison | Eligibility | NCT00880464 | NCT00458237 | HIV+ Patients are excluded from both the secondary trial and the primary trial. | Entailment | [
14,
18
] | [
12,
26
] | {'Clinical Trial ID': 'NCT00880464', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', 'Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out', ' Autologous, Lethally Irradiated Breast Cancer... | {'Clinical Trial ID': 'NCT00458237', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Everolimus (Dose Level 1) and Trastuzumab', ' Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are... | 5deb8ebd-fbd2-4d84-8ad2-a1248426908b |
Comparison | Eligibility | NCT00365417 | NCT00853996 | To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN and Hemoglobin > 10 g/dL. | Entailment | [
11,
13,
14,
9,
10
] | [
17,
18,
20,
23
] | {'Clinical Trial ID': 'NCT00365417', 'Intervention': ['INTERVENTION 1: ', ' Neoadjuvant Study Treatment', ' Doxorubicin, cyclophosphamide, and bevacizumab followed by docetaxel and capecitabine'], 'Eligibility': ['Inclusion Criteria:', ' Patients must be female.', ' The patient must be greater than/equal to 18 year... | {'Clinical Trial ID': 'NCT00853996', 'Intervention': ['INTERVENTION 1: ', ' Prevention (Acolbifene Hydrochloride)', ' Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.', ' acolbifene hydrochloride: Given orally'], 'Eligibility': ['Inclusion Criteria:', ' ... | 5f4880ac-1ce2-4b89-841b-a9918720b6ea |
Single | Intervention | NCT01441596 | Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01441596', 'Intervention': ['INTERVENTION 1: ', ' Afatinib Mono', ' Afatinib monotherapy administered orally: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.', 'INTERVENTION 2: ', ' Afatinib+Vino', ' Afatinib 40... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b3aabfaa-23cb-4a75-8416-761d8574f0a4 | |
Single | Results | NCT00524303 | The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00524303', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter). Participants were treated with trastuzumab in a 2-we... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f697c2d8-e0dd-476e-8ff4-dffe053076f8 | |
Comparison | Intervention | NCT02835625 | NCT00486525 | the primary trial and the secondary trial do not use chemotherapy, radiotherapy or mammography in their interventions | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT02835625', 'Intervention': ['INTERVENTION 1: ', ' Digital Breast Tomosynthesis', ' Digital Breast Tomosynthesis + Synthetic Mammography (DBT)', ' The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.', ' Women selected for furth... | {'Clinical Trial ID': 'NCT00486525', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Yoga Therapy', ' Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients were also encouraged to practice yoga at home. Patients recorded their total home/class practice time in weekly logs.', ... | f2c0f753-1775-42af-94f0-b87b20156e65 |
Single | Eligibility | NCT01028352 | Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, are eligible for the primary trial. | Entailment | [
0,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT01028352', 'Intervention': ['INTERVENTION 1: ', ' Duloxetine', ' Participants took 30 mg oral capsules once a day for 7 days, then 60 mg per mouth once per day for 21 days. After 4 weeks if pain had decreased, subjects continued 60 mg. per mouth once per day for 4 weeks. If pain had not decr... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 17b31c1d-db62-4628-b390-02da22512079 | |
Comparison | Intervention | NCT00574145 | NCT03167359 | Radiotherapy is used in all cohorts of the primary trial and the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00574145', 'Intervention': ['INTERVENTION 1: ', ' Radiotherapy/Supportive Care (A)', ' Patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapy', 'INTERVENTION 2: ', ' Control ARM (B)', ' Patients receive radi... | {'Clinical Trial ID': 'NCT03167359', 'Intervention': ['INTERVENTION 1: ', ' Participants With Stage 0-III Breast Cancer', ' Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.', ' Hypofractionated Simultane... | 2e6e1044-8b4a-41f7-8319-85fc5bba4482 |
Comparison | Adverse Events | NCT00493649 | NCT01201265 | There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT00493649', 'Intervention': ['INTERVENTION 1: ', ' TOP2A-amplified Group', ' FISH ratio of TOP2A gene copy number was 2 or greater.', 'INTERVENTION 2: ', ' TOP2A-nonamplified Group', ' FISH ratio of TOP2A gene copy number was less than 2.'], 'Eligibility': ['Inclusion Criteria:', ' A woman... | {'Clinical Trial ID': 'NCT01201265', 'Intervention': ['INTERVENTION 1: ', ' All Participants', ' Participants received a combination therapy of bevacizumab 15 milligram per kilogram (mg/kg) intravenous every 3 weeks with carboplatin recommended dose (area under curve [AUC]= 2) along with gemcitabine 1000 mg/ metre sq... | 456c6011-52bb-4c8b-9e82-e5a85cbbe0e3 |
Single | Intervention | NCT03618017 | the primary trial's intervention section does not describe the intervention dosage, frequency or duration. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT03618017', 'Intervention': ['INTERVENTION 1: ', ' Recruitment Population', ' Pre-randomization recruitment and enrollment'], 'Eligibility': ['Inclusion Criteria:', ' Diagnosed with early Stage (0-IIB) breast cancer', ' Must be a patient of a University of Michigan Breast Cancer Oncologist'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0c0324d2-0672-45cb-b715-e51e48786afb | |
Single | Adverse Events | NCT01421472 | Over 9 patients in the primary trial suffered from adverse events associated with a low number of white blood cells present in the bloodstream. | Contradiction | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT01421472', 'Intervention': ['INTERVENTION 1: ', ' HR+: MM-121+ Paclitaxel', ' Hormone-receptor positive (HR+) sub-group randomized to receive:', ' 2 week run-in of MM-121 (20 mg/kg weekly IV infusion over 60 minutes following a 40 mg/kg loading dose), followed by 4 cycles of MM-121 (20 mg/k... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b3bd3522-8731-448a-bade-a5a350697a98 | |
Comparison | Intervention | NCT01572038 | NCT00826267 | Each patient in the primary trial receives 3 different drugs, whereas in the secondary trial patients are given supportive-expressive group psychotherapy instead. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01572038', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab + Taxane', " Participants received pertuzumab and trastuzumab intravenously (IV) plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study end, unacceptable toxicity, withdrawal of cons... | {'Clinical Trial ID': 'NCT00826267', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 50 mg', ' Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course. 2 treatment courses were to be given in the trial.', 'INTERVENTION 2: ', ' Lapatinib 1500 mg', ' Patients... | 8607e8c1-6e99-49be-a63e-e707856c805a |
Single | Results | NCT03252431 | On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT03252431', 'Intervention': ['INTERVENTION 1: ', ' F-627', ' F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.', ' F-627: single dose pre-filled syringe', 'INTERVENTION 2: ', ' Neulasta', ' 6 mg fixed dose Neulasta®, administered on Day 2 o... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1c26e1a7-9d77-46ff-b1c6-179ece7c190f | |
Single | Adverse Events | NCT00191789 | In cohort 2 and 3 of the primary trial there was only case 1 of jaundice. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00191789', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine+Doxorubicin+Cisplatin+Surgery', ' Gemcitabine: 1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8).', ' Doxorubicin: 60 mg/m^2, IV, eve... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0a156ee2-eb90-40d2-9802-27b9b4a42ff3 | |
Comparison | Adverse Events | NCT00266110 | NCT00879086 | the primary trial and the secondary trial have entirely different adverse event reports. | Entailment | [
0,
1,
2,
3,
4
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT00266110', 'Intervention': ['INTERVENTION 1: ', ' Dendritic Cell Vaccine', ' Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion', ' sargramostim: All patients will receive Leuk... | {'Clinical Trial ID': 'NCT00879086', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate was given at a dose of 1.4 mg/m^2 as a 2 to 5 minute IV bolus on Days 1 and 8 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cy... | 82895f11-37bf-4d03-8de2-84818d93cce0 |
Comparison | Adverse Events | NCT00878709 | NCT02447003 | the primary trial had a total of 3 patients experiencing Pancreatic Cancer, the secondary trial had 0. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26
] | {'Clinical Trial ID': 'NCT00878709', 'Intervention': ['INTERVENTION 1: ', ' Neratinib', ' Patients who completed prior adjuvant trastuzumab received six 40 mg neratinib tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxici... | {'Clinical Trial ID': 'NCT02447003', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Pembrolizumab', ' Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants were administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle ... | f94643de-7122-4a58-972d-b0bb7e59d441 |
Comparison | Intervention | NCT01869764 | NCT02556632 | Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT01869764', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Omega-3 Fatty Acid)', ' Patients receive omega-3 fatty acid PO daily for 7-14 days.', 'omega-3 fatty acid: Given PO', ' laboratory biomarker analysis: Correlative studies', 'INTERVENTION 2: ', ' Arm II (Placebo)', ' Patients receive... | {'Clinical Trial ID': 'NCT02556632', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Curcumin-based Gel)', ' Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.', 'Curcumin-based ... | 1485315b-3169-42a3-a672-6f7963d49a51 |
Single | Eligibility | NCT03719677 | Potential participants will be considered regardless of the hormone receptivity of their breast cancer. | Contradiction | [
7
] | [] | {'Clinical Trial ID': 'NCT03719677', 'Intervention': ['INTERVENTION 1: ', ' Habit Development Intervention', ' Treatment includes occupational therapy evaluation and consultation to address any deficits in physical function, safety, social participation and/or life roles. After the occupational therapy evaluation, th... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b4ef27ca-52b4-4af3-9b60-e9e0285e0e86 | |
Single | Eligibility | NCT03371732 | patients with Karnofsky Index = 72 are eligible for the primary trial. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT03371732', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Arm 1: Motivational Intervention group', ' Motivational Intervention group: Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 769bb3b2-9d2d-4dad-bd59-0042c55ac1ee | |
Comparison | Eligibility | NCT00899574 | NCT01007942 | the primary trial uses different inclusion criteria for its cohorts, the secondary trial only uses one set on inclusion criteria for all cohorts. | Entailment | [
0,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | {'Clinical Trial ID': 'NCT00899574', 'Intervention': ['INTERVENTION 1: ', ' Imiquimod', ' Each treatment cycle consists of 8 weeks.', ' Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.', ' Patients with responding or stable local disease (non-progres... | {'Clinical Trial ID': 'NCT01007942', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Vinorelbine + Trastuzumab', ' Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)', 'INTERVENTION 2: ', ' Pl... | 426196d8-44ab-4c5c-8f81-5cb12345ad69 |
Comparison | Adverse Events | NCT00365365 | NCT00005908 | the primary trial and the secondary trial only recorded one type of acute adverse event. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00365365', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1 (AC->T + Bevacizumab)', ' HER2-negative participants administered', ' doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by', ' docetaxel (T) + bevacizumab for 4 cycles followed by', ' bevacizumab maintenan... | {'Clinical Trial ID': 'NCT00005908', 'Intervention': ['INTERVENTION 1: ', ' Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine', ' Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles Once the dose was deemed to be too toxic, subsequent patients were enrolled on dose B.... | bcf433b6-4029-4d00-9ccf-d8d94f1722d8 |
Single | Results | NCT01605396 | The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01605396', 'Intervention': ['INTERVENTION 1: ', ' Ridaforolimus + Dalotuzumab + Exemestane', ' Participants received ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles unt... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1268edfc-cce2-4f07-9fbb-392341b7f399 | |
Single | Adverse Events | NCT01276041 | 1 patient in the primary trial died in an event not associated with a specifc CTCAE term. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT01276041', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab in Combination With Trastuzumab and Paclitaxel', ' This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.'], 'Eligibility': ['Inclus... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 58ccfd13-aa6d-4604-bf3d-c69270fe50d2 | |
Comparison | Adverse Events | NCT00182793 | NCT00509769 | The majority of patients in the primary trial and the secondary trial experienced an adverse event. | Contradiction | [
0,
1
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT00182793', 'Intervention': ['INTERVENTION 1: ', ' All Patients', ' Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®), one day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation, no more th... | {'Clinical Trial ID': 'NCT00509769', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine 3.6 mg/kg', " Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle."], 'Eligib... | a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249 |
Single | Eligibility | NCT01105312 | Patients with measurable diseases are only eligible for phase 2 of the primary trial. | Contradiction | [
5,
6
] | [] | {'Clinical Trial ID': 'NCT01105312', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dose Level One', ' Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered 20 mg LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8c84c96f-1635-40dc-839b-fc937ed566a2 | |
Single | Adverse Events | NCT00320710 | There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients. | Entailment | [
13,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00320710', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid Every (q) 4 Weeks', ' Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.', 'INTERVENTION 2: ', ' Zoledronic Acid q 12 Weeks', ' Participants received 4 mg zoledronic acid IV q 12 weeks and re... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7b48355e-3b9c-4cca-b7fa-1cbd612d1523 | |
Single | Eligibility | NCT00617539 | Presence of Extracranial metastases is part of the exclusion critera for the primary trial. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00617539', 'Intervention': ['INTERVENTION 1: ', ' Irinotecan and Temozolomide', ' irinotecan hydrochloride administered intravenously (IV) at a starting dose of 125 mg/m2 on days 1 and 15 of a 28 day cycle', ' temozolomide orally for seven days at a starting dose of 100 mg/m2 on days 1-7 an... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3d188d93-13c6-48f3-b231-dcdeef81080e | |
Single | Intervention | NCT01209195 | Lower doses of MM-121 and Paclitaxel are utilised in cohort1 of the primary trial than in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT01209195', 'Intervention': ['INTERVENTION 1: ', ' Part 1: Dose Escalation: Cohort 1', ' MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV', 'INTERVENTION 2: ', ' Part 1: Dose Escalation: Cohort 2', ' MM-121 - 40 mg/kg loading dose followed by 20 m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d7e81d80-5cbf-4969-be00-4fdf17aa4eb9 | |
Single | Eligibility | NCT00101400 | A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/µl and total bilirubin > 1.6 x ULN are eligilbe for the primary trial. | Entailment | [
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00101400', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib (Nexavar, BAY43-9006)', ' Sorafenib 400 mg administered twice daily (b.i.d.)'], 'Eligibility': ['Inclusion Criteria:', ' Age > 18 years', ' Women with prior histologically documented diagnosis of breast cancer', ' Subjects with m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2206dc2a-93da-4c11-b110-81f9c39af807 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.